The continued rise in chronic and high-cost conditions remain primary drivers of escalating medical costs in the United States.

A primary contributor is the lack of competition in the pharmaceutical market, especially for brand-name drugs protected by patents.

Although it helps provide preventive services, manage chronic conditions and coordinate patient care, the United States trails other high-income nations in total health care spending for primary care.

“In today’s competitive market, employers are seeking to balance employees’ benefits expectations with escalating costs,” according to the 2025 Benefit Plan Trends Survey from USI.

Analysts attribute the increase to consistent savings and positive stock market performance, despite market volatility at the beginning of the quarter.

Aetna and Optum have finalized a nearly $8.4 million settlement in a class-action lawsuit that has been litigated for almost a decade.

A class-action lawsuit was filed last week against CVS Caremark in the Southern District of New York over its decision to replace Eli Lilly’s popular GLP-1 weight-loss drug Zepbound with Wegovy from Novo Nordisk.

The plaintiffs alleged that the company and State Street Global Advisors violated fiduciary requirements under the Employee Retirement Income Security Act.